
Topic
GLP-1
Semaglutide, tirzepatide, oral GLP-1 candidates, supply capacity, coverage pressure, and the access systems around metabolic drugs.

Pricing & Access· June 6, 2026 · 12 min read
By Ran Chen#GLP-1#UnitedHealthcare#UHC

Pricing & Access· June 6, 2026 · 11 min read
VA GLP-1 coverage: formulary status, non-formulary Wegovy criteria, and CHAMPVA rules
By Ran Chen#GLP-1#Veterans Affairs#Prior Authorization

Pricing & Access· June 5, 2026 · 15 min read
Rybelsus coverage guide: oral semaglutide access, formulary tiers, and prior authorization
By Ran Chen#GLP-1#Payer Coverage#Prior Authorization

Policy· June 4, 2026 · 13 min read
Medicare Part D GLP-1 coverage policy and the 2026 Bridge
By Ran Chen#GLP-1#Medicare Part D#Payer Coverage

Pricing & Access· June 4, 2026 · 13 min read
Ozempic prior authorization checklist for 2026
By Ran Chen#GLP-1#Prior Authorization#Payer Coverage

Pricing & Access· June 3, 2026 · 15 min read
GLP-1 insurance coverage 2026: major payer guide
By Ran Chen#GLP-1#Payer Coverage#Prior Authorization

Pricing & Access· May 31, 2026 · 14 min read
Switching from compounded GLP-1s to FDA-approved therapy
By Ran Chen#GLP-1#FDA Approval#Market Access

Pricing & Access· May 31, 2026 · 12 min read
GLP-1 appeal evidence after cardiometabolic comorbidity denial
By Ran Chen#GLP-1#Prior Authorization#Specialty Drugs

Pricing & Access· May 31, 2026 · 13 min read
GLP-1 reauthorization after BMI drops below the original threshold
By Ran Chen#GLP-1#Prior Authorization#Medicare Part D

Pricing & Access· May 31, 2026 · 12 min read
GLP-1 restart after treatment interruption: PA documentation and dosing
By Ran Chen#GLP-1#Prior Authorization#Specialty Drugs